Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NT5E | P21589 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723443 | 0.72 | — | — | |
| SCHEMBL309011 | 0.72 | — | — | |
| SCHEMBL17112672 | 0.68 | — | — | |
| SCHEMBL1765938 | 0.68 | — | — | |
| SCHEMBL1934832 | 0.68 | — | — | |
| SCHEMBL10017208 | 0.68 | — | — | |
| SCHEMBL8627156 | 0.67 | KDM4E (0.39) | TSHRCYP3A4BLMKDM4EHSD17B10 | |
| Hydrochloric Acid SCHEMBL9534244 | 0.67 | TSHR (0.50) | TSHRCYP3A4BLML3MBTL1CHEK1 | |
| Cytosine SCHEMBL10411159 | 0.64 | DYRK1A (0.38) | TSHRPNPKDM4EGAANT5E | |
| SCHEMBL313299 | 0.64 | TSHR (0.47) | TSHRCYP3A4BLMCHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250297288-A1 | GENOME EDITING OF B CELLS | EDITAS MEDICINE, INC. | 2025-09-25 | — | — | US | disclosed |
| US-12338436-B2 | Synthetic guide molecules, compositions and methods relating thereto | EDITAS MEDICINE, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2025128661-A1 | COMPOSITIONS AND METHODS FOR TARGETING ASTROCYTES TO TREAT NEUROLOGICAL DISORDERS | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-19 | — | — | WO | disclosed |
| WO-2025106853-A1 | CAS12A NICKASE PROTEINS AND USES THEREOF | EDITAS MEDICINE, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4522736-A2 | GENOME EDITING OF B CELLS | Editas Medicine, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250025572-A1 | ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOF | EDITAS MEDICINE, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-4441209-A1 | ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOF | Editas Medicine, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20240293543-A1 | ENGINEERED CELLS FOR THERAPY | EDITAS MEDICINE, INC. | 2024-09-05 | — | — | US | disclosed |
| WO-2014020124-A1 | MEANS AND METHODS FOR THE DETECTION OF DNA METHYLATION | UNIVERSITAET KONSTANZ (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-20110117659-A1 | QUINAZOLINE-CONTAINING KITS FOR LABELING ALDEHYDE OR KETONE MOIETIES | Life Technologies Corporation (US) | 2011-05-19 | — | — | US | disclosed |
| US-7816527-B2 | Quinazoline-containing kits for labeling aldehyde or ketone moieties | Life Technologies Corporation (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1658383-A1 | IMPROVED BISULFITE METHOD EMPLOYING SIZE EXCLUSION STEP | Applera Corporation, Applied Biosystems Group (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6967251-B2 | Reagents for labeling biomolecules having aldehyde or ketone moieties | MOLECULAR PROBES, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050250152-A1 | Reagents for labeling biomolecules having aldehyde or ketone moieties | MOLECULAR PROBES, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005021803-A1 | IMPROVED BISULFITE METHOD EMPLOYING SIZE EXCLUSION STEP | APPLERA CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1322625-A2 | REAGENTS FOR LABELING BIOMOLECULES HAVING ALDEHYDE OR KETONE MOIETIES | Molecular Probes Inc. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020137068-A1 | Reagents for labeling biomolecules having aldehyde or ketone Moieties | MOLECULAR PROBES, INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002028841-A2 | REAGENTS FOR LABELING BIOMOLECULES HAVING ALDEHYDE OR KETONE MOIETIES | MOLECULAR PROBES, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250297288-A1 | GENOME EDITING OF B CELLS | BCL6, BCR, BCL6B | TSHR 4333/4885CYP3A4 4827/4885BLM 2522/4885 |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | TSHR 3816/4885CYP3A4 4641/4885BLM 275/4885 |
| US-20250025572-A1 | ENGINEERED CRISPR/CAS12A EFFECTOR PROTEINS, AND USES THEREOF | CDA, GDA, DAB2IP | TSHR 3639/4885CYP3A4 3333/4885BLM 1806/4885 |
| US-20020137068-A1 | Reagents for labeling biomolecules having aldehyde or ketone Moieties | DERA, HLCS, CD44 | TSHR 3709/4885CYP3A4 3897/4885BLM 2841/4885 |
| US-20240293543-A1 | ENGINEERED CELLS FOR THERAPY | HAVCR2, CD47, IL2RA | TSHR 2336/4885CYP3A4 4711/4885BLM 1318/4885 |
| US-20050250152-A1 | Reagents for labeling biomolecules having aldehyde or ketone moieties | QPCTL, FGB, QPCT | TSHR 660/4885CYP3A4 3004/4885BLM 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.